| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2018-06-28 | IFX-1 | ANCA-associated vasculitis (AAV) | 2 | InflaRx (Germany) | Autoimmune diseases - Cardiovascular diseases - Rare diseases |
| 2018-06-27 | Emgality™ (galcanezumab-gnlm - LY2951742) | episodic migraine, chronic migraine | 3 | Eli Lilly (USA - IN) | CNS diseases - Neurological diseases |
| 2018-06-26 | AT-GAA (ATB200/AT2221) | Pompe disease | 1-2 | Amicus Therapeutics (USA - NJ) | Genetic diseases - Rare diseases - Metabolic diseases |
| 2018-06-25 | GNbAC1 | type 1 diabetes | preclinical | Geneuro (Switzerland) | Autoimmune diseases - Metabolic diseases |
| 2018-06-25 | G100 | indolent non-Hodgkin Follicular lymphomas (FL) | preclinical | Immune Design (USA - MA) | Cancer - Oncology |
| 2018-06-20 | aprocitentan | resistant hypertension management in adults | 3 | Idorsia (Switzerland) | Cardiovascular diseases |
| 2018-06-18 | clazosentan | prevention of clinical deterioration due to vasospasm-related delayed cerebral ischemia in patients following an aneurysmal subarachnoid hemorrhage | 3 | Idorsia (Switzerland) | Cerebrovascular diseases |
| 2018-06-18 | remetinostat | early-stage cutaneous T-cell lymphoma (CTCL). | 3 | Medivir (Sweden) | Cancer - Oncology |
| 2018-06-18 | remetinostat | early-stage cutaneous T-cell lymphoma (CTCL). | 3 | Medivir (Sweden) | Cancer - Oncology |
| 2018-06-15 | LentiGlobin® BB305 (autologous CD34+ haematopoietic stem cells transduced with lentiviral vector encoding the human beta A-T87Q-globin gene) | transfusion-dependent beta-thalassemia with non-Beta0/Beta0 genotypes | 3 | Bluebird bio (USA - MA) | Rare diseases - Genetic diseases - Hematological diseases |
| 2018-06-15 | LentiGlobin® BB305 (autologous CD34+ haematopoietic stem cells transduced with lentiviral vector encoding the human beta A-T87Q-globin gene) | beta-thalassemia | 1-2 | bluebird bio (USA - MA) | Hematologic diseases - Genetic diseases - Rare diseases |
| 2018-06-15 | LentiGlobin® BB305 (autologous CD34+ haematopoietic stem cells transduced with lentiviral vector encoding the human beta A-T87Q-globin gene) | sickle cell disease | 1 | bluebird bio (USA - MA) | Genetic diseases - Hematological diseases - Rare diseases |
| 2018-06-12 | CubiCAR | preclinical | Cellectis (France) | ||
| 2018-06-04 | Ad-RTS-hIL-12 + veledimex - adenoviral vector-RheoSwitch Therapeutic System-human interleukin 12 + veledimex | patients with recurrent or progressive glioblastoma or Grade III malignant glioma | 1 | Ziopharm Oncology (USA - MA) | Cancer - Oncology - Rare diseases |
| 2018-06-04 | Ad-RTS-hIL-12 + veledimex - adenoviral vector-RheoSwitch Therapeutic System-human interleukin 12 + veledimex | patients with locally advanced or metastatic breast cancer | 1b-2 | Ziopharm Oncology (USA - MA) | Cancer - Oncology |
| 2018-06-04 | RE-024 Fosmetpantotenate | pantothenate kinase-associated neurodegeneration (PKAN) | 3 | Retrophin (USA - CA) | Rare diseases - Genetic diseases - Neurological diseases |
| 2018-06-04 | epacadostat and nivolumab | advanced solid tumors and lymphomas, including melanoma (MEL), non-small cell lung cancer (NSCLC), colorectal cancer (CRC), squamous cell carcinoma of the head and neck (SCCHN), ovarian cancer (OC), and B cell non-Hodgkin lymphoma ( NHL ) or Hodgkin lymphoma (HL) | 1-2 | BMS (USA - NY) Incyte (USA - DE) | Cancer - Oncology |
| 2018-06-03 | durvalumab (MEDI4736) and monalizumab (IPH2201/anti-NKG2A) | advanced solid tumors | 1 | AstraZeneca (UK) Innate Pharma (France) | Cancer - Oncology |
| 2018-06-03 | tazemetostat - EPZ-6438 (E7438) | relapsed/refractory malignant mesothelioma patients with BRCA1-associated protein 1 (BAP1) loss-of-function | 2 | Epizyme (USA - MA) | Cancer - Oncology - Rare diseases |
| 2018-06-01 | bb2121 anti-BCMA CAR T cells | multiple myeloma | 1 | Bluebird bio (USA - MA) Celgene (USA - NJ) | Cancer - Oncology |
